What is PaxMedica, Inc. Common Stock (PXMD)?

PaxMedica, Inc. Common Stock (PXMD) is a stock in the Healthcare sector, Biotechnology industry. View full analysis on Stocks360.

What is the current price of PXMD?

The current price of PXMD is $0.00. Prices are updated in real time on Stocks360.

What is PXMD's price-to-earnings (PE) ratio?

PXMD's trailing twelve-month PE ratio is -0.00, based on current price and earnings per share data available on Stocks360.

What is PXMD's market capitalization?

PXMD's market capitalization is $88,385.00, placing it in the small-cap tier.

PaxMedica, Inc. Common Stock (PXMD)

Stock analysis · OTC · Healthcare · Biotechnology

$0.00

Market Cap

$88.39K

PE (TTM)

-0.00

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

-0.51

Day Range

$0.00 – $0.00

52-wk Range

$0.00 – $0.02

Avg Volume

N/A

Volume

300.00

PaxMedica, Inc. Common Stock (PXMD) is a publicly traded company in the Healthcare sector. Latest price: $0.00. Market cap $88.39K. Trailing PE -0.00. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

1-Year Price

2025-10-31 · $0.01 2026-10-29 · $0.00 (-86.00%)

Earnings

Most Recent

Sep 30, 2024

EPS $-0.39 vs est. $-0.30

Missed by $0.09

Next Earnings

Dec 2, 2026

EPS estimate $-0.88

Proprietary Signals

Signal snapshot temporarily unavailable.

About PaxMedica, Inc. Common Stock

PaxMedica, Inc. is a biopharmaceutical company currently in the clinical development phase, dedicated to advancing anti-purinergic drug therapies (APTs). These innovative treatments are specifically designed to address complex neurological disorders presenting with stubborn and persistent symptoms. The company's primary investigative drug is PAX-101, an intravenous (IV) form of suramin, which is being explored for a variety of conditions. These include autism spectrum disorder, myalgic encephalomyelitis/chronic fatigue syndrome, post-COVID-19 syndrome (commonly known as "long COVID"), and human African trypanosomiasis. Furthermore, PaxMedica is also developing PAX-102, an intranasal version of suramin, intended for various neurological applications. The company, which was incorporated in 2018 and has its headquarters in Tarrytown, New York, previously operated as Purinix Pharmaceuticals LLC before rebranding to PaxMedica, Inc. in April 2020. It functions as a subsidiary of Tardimed Sciences LLC.

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-0.00×
P/S (TTM)	0.00×
P/B	0.00×
P/FCF (TTM)	-0.01×
EV / EBITDA	0.29×
EV / Sales	0.00×
Earnings Yield	-1571170.86%
Free Cash Flow Yield	-12183.63%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	-$4.62M
Net Income (TTM)	-$1.39B
Free Cash Flow (TTM)	-$10.76M
Net Debt	-$4.71M
Working Capital	$3.89M
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Return on Equity	-1046.98%
Return on Invested Capital	-415.56%